Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Kunming Pharmaceutical named top 10 investment opportunity: Industry had 28.0% increase to 141.47 billion yuan.
Still not sure if this is the correct Kunming, but good article for health of the pharmaceutical industry.
August 25 hearing, China Pharmaceutical Enterprise Management Association's sixth most competitive Chinese top 20 pharmaceutical companies named Most Valuable cum 2014 annual pharmaceutical companies announced selection, Hengrui Medicine (600276.SH), Tasly (600535.SH) and other selected.
Statistics show that the competitiveness of pharmaceutical companies 20 companies in 2013 total revenue 141.47 billion yuan, an increase of 28.0%, total net profit 20.65 billion yuan, an increase of 19.4%, significantly higher than the overall growth rate of the pharmaceutical companies and the pharmaceutical industry listed. Among them, the main business of the size of more than 5 billion yuan of 11, more than 10 billion yuan has four, Baiyun Mountain (600332.SH) main business revenue among the top 20, reaching 17.608 billion yuan.
Selected the top 20 A-share listed companies include: Tasly, red medicine (300026.SZ), Yunnan Baiyao (000538.SZ), Salubris (002294.SZ), HRH medicine, donkey-hide gelatin (000,423. SZ), Health America Pharmaceutical (600518.SH), Yibai Pharmaceutical (600594.SH), Tomson times (300146.SZ), Xinhua Medical (600587.SH), Hai Sike (002653.SZ), Fosun Pharmaceutical ( 600196.SH), Tong Ren Tang (600085.SH), Tiantan Biological Products (600161.SH) and China Resources thirty-nine (000999.SZ).
Also, according to industry experts, analysts, institutional investors to vote, selected the top 10 list of the most investment value pharmaceutical companies 2014 annual A-share listed companies, including: HRH medicine, East China Pharmaceutical (000963.SZ), Tat gene ( 002030.SZ), Kang edge medicine (600557.SH), Ireland Eye (300015.SZ), wide reputation far (600771.SH), Kunming Pharmaceutical (600422.SH), Tasly and John Hancock Medical (002219.SZ) .
I am not an expert in shorting, in fact I know very little. However, I have an educated guess on what has been happening with the stock the last few days. On why it drops and then comes back up at the end of the day.
I think someone is shorting the stock with hopes of creating some downward action. They know by doing this during trading hours that is a fairly safe bet. It is unlikely any big new money is going to come into FCPG without any news, and any significant news tends to come out after hours.
This allows them to closely monitor it during hours. At the end of the day they close out their short position to prevent exposure of news breaking after hours, and this sends the price back up.
The strategy is good. The problem they are facing is that there really is just a handful of people who own any position in FCPG, and those that do are educated to the circumstances. For the most part, those of us that are holding shares have already decided to just ride it out. Either the financials will be released and we are going to make a lot of money, or they will never be released and we will lose everything that we have put in.
Fortunately, it appears that there are a number of factors that create a likelihood that the financials will be released, and sometime soon! Nevertheless, it is still a speculative bet.
One of the biggest problems the Longs face is that we expect Communist China and their companies to behave like they are in America. The truth is, there are number of factors we can’t control even if the financials are released.
With that said, the upside still appears to enormous.
FCPG is severally undervalued because the sum of its parts has to be worth more than the current 3 million market cap. Their new facility is likely worth more that alone.
The price is solely reflective of the lack of communication. However, we have seen nothing to indicate FCPG is no longer growing. If they are growing, than it is extremely undervalued.
Regardless, it all comes down to communication. If nothing is reported by the 1st Qtr of next year, then we are likely headed to sub penny land.
This is just a test. The board seems broken with no new posts and not updating the price or volume today.
Legalization leads in pools according to this article, DC, 3 states, and a US territory will vote on marijuana this year
Several of you have pointed to the day after elections next week as when this stock will jump. You may be right.
However, the one thing I have learned as a paid NFL expert is that there are almost no true experts in any field that predicts the future. Everything is just educated conjecture. So, I hope your educated guesses of an up-word trajectory for CANCV are correct.
Link to article with text below:
http://www.vox.com/2014/7/23/5929817/medical-marijuana-legalization-2014
This year, several more states will vote on whether marijuana should be legal for recreational and medical purposes. Given that more Americans favor legalization than ever, these ballot initiatives have a real chance of passing.
Here are the statewide initiatives that will appear on ballots on November 4, listed in alphabetical order.
Alaska will vote on full legalization
109923360
Alaska may even more green come November. (McClatchy-Tribune via Getty Images)
Alaska's Issue 2 would allow adults 21 and older to possess up to one ounce of pot and maintain six marijuana plants. The measure would legalize production and sales, which the Alcoholic Beverage Control Board — or a Marijuana Control Board, if one is created — would regulate. The measure would also tax marijuana at the point of sales at $50 per ounce.
One poll commissioned by the Alaska House Majority Caucus found 52 percent of Alaskan voters support legalization, while 44 percent oppose it and 4 percent are undecided. Another poll from Public Policy Polling (PPP) found a closer battle: 48 percent support legalization, 45 percent do not, and 7 percent are undecided.
If voters approve the initiative, Alaska would become the first red state with full legalization. Learn more about Alaska's history with marijuana, including why it was one of the first states to decriminalize pot, here.
The District of Columbia will vote on legalization
142151464
A medical marijuana dispensary in DC. (Alex Wong / Getty Images News)
DC's Initiative 71 would allow adults 21 and older to possess up to two ounces of marijuana, grow up to six plants, and gift marijuana to other adults 21 and older. It would not legalize sales, because voter initiatives in DC can't deal with that issue.
A Washington Post poll found marijuana legalization is favored by DC residents almost two-to-one, which was later backed by a more recent poll from NBC4, the Washington Post, and Marist.
DC Council decriminalized marijuana this year, but supporters of legalization argue the measure doesn't go far enough. Law enforcement in some states, for example, have been able to use loopholes in decriminalization laws to continue arresting minorities at disproportional rates.
Florida will vote on medical marijuana
105203985
A Floridian shows support for marijuana legalization. (Joe Raedle / Getty Images News)
Florida's Issue 2 would legalize marijuana to treat "debilitating medical condition" such as cancer, multiple sclerosis, glaucoma, hepatitis C, HIV, AIDS, amyotrophic lateral sclerosis, Crohn's disease, Parkinson's disease, or "other conditions for which a physician believes that the medical use of marijuana would likely outweigh the potential health risks for a patient." The Florida Department of Health would set up regulations for medical marijuana cards and treatment centers.
A poll conducted for the pro-medical marijuana campaign found seven in 10 Florida voters support the initiative, and another survey from PPP found 66 percent support the measure.
Florida passed a very limited medical marijuana law earlier this year that allows a narrow pool of qualifying patients to use a strain of marijuana that's low in THC, which is the psychoactive ingredient of the drug, for medicinal purposes. But the law is so limited that major legalization advocates, including the Marijuana Policy Project and NORML, don't consider Florida a medical marijuana state.
Guam will vote on medical marijuana
166292317
Could a medical marijuana dispensary be in this tourist hotspot's future? (AFP via Getty Images)
Guam's ballot initiative would legalize marijuana to treat "debilitating medical conditions" like cancer, glaucoma, multiple sclerosis, epilepsy, HIV, arthritis, and PTSD. A government commission would later establish rules and regulations for how the marijuana will be distributed through dispensaries.
A survey conducted by Ron McNinch from the University of Guam found 62 percent of Guam voters support the measure.
Since Guam is a US territory and not a state, the measure ran through some legal hurdles before the Supreme Court of Guam ruled in favor of the initiative and the local election board agreed to put it on the ballot. Unlike a typical ballot initiative, it was not taken to the election board through petitioning; instead, the Guam legislature unilaterally put the measure on the ballot.
Oregon will vote on full legalization
140118297
Some places in Oregon value being eccentric. (George Rose / Getty Images News)
Oregon's ballot initiative would allow adults 21 and older to possess up to eight ounces and four plants of marijuana. It would also legalize production and sales, which the Oregon Liquor Control Commission would regulate. The measure would also tax marijuana at the point of sales at $35 per ounce.
One poll from SurveyUSA found 51 percent of Oregon voters support legalization and 41 percent oppose it, but the poll didn't use the initiative's specific language.
Oregon was one of the three states with legalization initiatives on the ballot in 2012. But the 2012 measure received no support from national advocacy groups, who said it was poorly written, and it failed. This year's initiative, in contrast, has support from the Drug Policy Alliance.
All of these proposals only affect state law. Federal law still prohibits marijuana, although the federal restrictions are currently under review. To learn more, read our full explainer and watch the video below:
The two companies look exactly the same. How can I tell the difference?
Thanks for clearing that up
It sure is confusing with similar names and using Google Translate. Maybe I should leave that up to Novice.
Revenue of 33,736,682.64 USD in 3rd Qtr. for Kunming Pharmaceutical Group Co., Ltd.
I don't mean to confuse things, so I apologize if I have the wrong company. However, I think I just found the current financials for the 3rd Qtr for Kunming Pharmaceutical Group.
Kunming Pharmaceutical Group Co., Ltd.
http://finance.sina.com.cn/stock/t/20141022/010020602347.shtml
An Important Notice
1.1 Board of Directors, supervisors and directors, supervisors and senior management personnel shall guarantee the authenticity of this quarterly report, accurate, complete, and there is no false records, misleading statements or material omissions, and assume joint and several liability.
1.2 All directors attended the Board of Directors reviewed the quarterly report.
1.3 The person in charge of HE Qin, director of accounting and Wang Shao-wide accounting department (accounting officer) Zhu Youqiang guarantee financial statements quarterly report is true, accurate and complete.
1.4 The third quarterly report is unaudited.
Second, changes in key financial data and company shareholders
2.1 Key Financial Data
Unit: Currency: RMB
This reporting period
End of last year
Over the end of the reporting period the previous year change (%)
Total assets
2,922,875,251.39
2,885,839,475.35
1.28
Net assets attributable to shareholders of listed companies
1,841,760,489.85
1,757,991,412.79
4.77
Year to the end of the period
(January to September)
The beginning of the reporting period to the previous year
(January to September)
Than last year (%)
Net cash flow from operating activities
206,151,436.86
128,917,517.89
59.91
Year to the end of the period
(January to September)
The beginning of the reporting period to the previous year
(January to September)
Decrease over the previous year
(%)
Operating income
2,904,622,676.29
2,598,663,326.47
11.77
Net profit attributable to shareholders of listed companies
203,165,839.01
163,624,521.24
24.17
Net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses
174,551,637.39
159,074,110.41
9.73
Weighted average return on net assets (%)
10.93
14.37
3.44 percentage point reduction
Basic earnings per share (RMB / share)
0.5956
0.4797
24.16
Diluted earnings per share (RMB / share)
0.5956
0.4797
24.16
The total number of shareholders and top ten shareholders and the top ten tradable shareholders 2.2 cutoff of the reporting period (or tradable shareholders) holding Fact Sheet
Unit: Share
Total number of shareholders (households)
15036
The top ten shareholders
Name of shareholder
Changes in the reporting period
Closing number of shares
Percentage (%)
Number of shares held by moratorium
Pledged or frozen
Nature of shareholders
(Full name)
Shares state
Quantity
Hua Fang Pharmaceutical Co., Ltd.
0
64,250,225
18.83
0
Freeze
6,000,000
Domestic non-state-owned legal person
Yunnan Hongta Group Co., Ltd.
0
29,991,365
8.79
0
Unknown
Domestic non-state-owned legal person
China Construction Bank(4.07, 0.03, 0.74%) Co., Ltd. - Manulife TEDA efficiency optimization hybrid securities investment fund
-1,732,740
10,956,337
3.21
0
Unknown
Other
China Industrial and Commercial Bank of China(3.54, 0.02, 0.57%) - Huitianfu Growth Securities Investment Fund
-4,004,690
9,500,000
2.78
0
Unknown
Other
Yunnan Industrial Investment Holding Group Co., Ltd.
0
5,287,108
1.55
0
Unknown
State-owned corporation
China Everbright Bank(2.69, 0.04, 1.51%) Co., Ltd. - optimal mix of resources, Morgan Stanley Huaxin Securities Investment Fund
-950,007
5,210,084
1.53
0
Unknown
Other
Bank of China(2.69, 0.05, 1.89%) - Franklin Templeton Sealand potential combination Securities Investment Fund
-1,435,599
5,000,000
1.47
0
Unknown
Other
Fujian Ping
4,954,903
1.45
0
Unknown
Domestic natural person
Bank of China - Harvest Theme Selected Mixed Securities Investment Fund
4,799,863
1.41
0
Unknown
Other
China Ping An(42.05, 1.34, 3.29%) Life Insurance Company Limited - Traditional - General Insurance
-5,900,400
4,700,316
1.38
0
Unknown
Other
Top ten tradable shareholders
Name of shareholder
Hold the number of tradable shares
The type and quantity of shares
Species
Quantity
Hua Fang Pharmaceutical Co., Ltd.
64,250,225
RMB ordinary shares
64,250,225
Yunnan Hongta Group Co., Ltd.
29,991,365
RMB ordinary shares
29,991,365
China Construction Bank Corporation [microblogging] - Manulife TEDA efficiency optimization hybrid securities investment fund
10,956,337
RMB ordinary shares
10,956,337
ICBC China - Huitianfu Growth Securities Investment Fund
9,500,000
RMB ordinary shares
9,500,000
Yunnan Industrial Investment Holding Group Co., Ltd.
5,287,108
RMB ordinary shares
5,287,108
China Everbright Bank Co., Ltd. - optimal mix of resources, Morgan Stanley Huaxin Securities Investment Fund
5,210,084
RMB ordinary shares
5,210,084
Bank of China - Franklin Templeton Sealand potential combination Securities Investment Fund
5,000,000
RMB ordinary shares
5,000,000
Fujian Ping
4,954,903
RMB ordinary shares
4,954,903
Bank of China - Harvest Theme Selected Mixed Securities Investment Fund
4,799,863
RMB ordinary shares
4,799,863
China Ping [microblogging] Life Insurance Company Limited - Traditional - General Insurance
4,700,316
RMB ordinary shares
4,700,316
The shareholders' association or the concerted action
Restoration of voting rights and number of shares of preferred shareholders description
Third, the important issues
3.1 The main financial statements and financial indicators and the reasons for significant changes
v Applicable ? NA
Unit: Currency: RMB
Account Name
Issue / Closing
The previous period / early
Changes in the ratio (%)
Reasons for change
Accounts receivable
472,633,488.86
362,618,240.41
30.34
Increase customer arrears issue
Other receivables
109,757,815.75
58,032,164.72
89.13
Margin increased land issue
Other current assets
396,114,411.41
552,503,364.83
-28.31
Reduce the current investment products
Fixed assets
398,823,870.41
301,889,674.38
32.11
Construction in progress carried forward
Construction in progress
90,097,591.07
192,450,644.14
-53.18
Construction in progress carried forward
Short-term borrowings
124,500,000.00
30,000,000.00
315.00
Increase in current loans
Long-term borrowings
24,500,000.00
0
Not applicable
This issue loans increased, the period without
Other payables
264,793,661.03
170,055,987.79
55.71
With revenue growth and growth
Business tax and surcharges
19,406,021.39
14,792,894.51
31.18
With revenue growth and growth
Financial expenses
8,820,278.17
20,203,985.02
-56.34
On repayment of short-term financial interest, no issue
Impairment losses on assets
2,478,232.36
6,020,247.04
-58.84
On equity of provision for impairment, no issue
Net cash flow from operating activities
206,151,436.86 or 33,736,682.64 USD
128,917,517.89
59.91
Increase the current cash payment
Net cash flow from investing activities
-147,867,599.21
-632,378,083.72
Not applicable
The current project expenditure reduced?
Net cash flow from financing activities
85,920,732.62
509,022,840.76
-83.12
The public issuance of shares, issue no?
3.2 Company and shareholder holding more than 5% of the fulfillment of commitments
v Applicable ? NA
Commitment background
Commitment type
Commitment party
Commitment Content
Commitment of time and deadlines
Are there performance period
Implementation of the commitments
Commitments associated with refinancing
Resolve intra-industry competition
Actual control
Actual control of the issuer for the current situation with the competition in terms of the presence of artemisinin, on December 24, 2012 commitment: "The current anti-malarial Artemisia annua industry charitable industry, mainly large international pharmaceutical company Novartis, Sanofi and other monopolies, the above related parties artemisinin business achieve lower annual profit, and therefore require long-term cultivation of listed companies will contribute to make the light of historical issues, in the next five years, according to artemisinin overall market conditions, companies annua prime business development, the degree of recognition of the capital market, through asset acquisitions, restructuring and other means, to develop specific operation of the program, step by step, so as to solve the Kunming system
Artemisinin drugs in terms of competition with the industry scenario. "To solve the issuer and the actual controller of other companies in the same industry in terms of artemisinin competition, the actual controller Wang Licheng on March 22, 2013 to be adopted in the following manner in order to avoid competition: (1) will continue to remain in Kunming Pharmaceuticals(26.81, 0.14, 0.52%) existing good corporate governance structure, fully maintain independence in Kunming Pharmaceutical assets, personnel, business, institutional, financial aspects, to ensure that listed companies Kunming Pharmaceutical norms by independent operators to ensure the Kunming Pharmaceutical an independent and complete business system and independent operators the ability to directly market-oriented; (2) the actual controller will be invested at fair treatment of all enterprises, and not used as the actual control status or use of information obtained in this position, make no conducive to the issuer and the decision in favor of other companies, if the issues related to the actual controller directly intervene in specific production and business activities of enterprises, which results in a loss of the issuer, the actual controller will take the responsibility; and (3) to take positive measures to eliminate the issuer and with the competition or potential competition with the status of artemisinin-based enterprises under the control of actual control between the specific measures including, but not limited to:. a In five years, that is, before 31 December 2017, and gradually to mergers and acquisitions, restructuring and business restructuring, etc., to complete the issuer Kunming Pharmaceutical application documents issuance of A shares prospectus assets and business 1-1-131 and the actual control under the control of artemisinin-based enterprise integration between .b. assist issuers the introduction of new external strategic investors to optimize corporate governance structure c. progressively to mergers and acquisitions, restructuring and business restructuring, etc., to complete the integration of the assets and business of the issuer under artemisinin-based enterprises and the actual control between control by the above measures over the next five years, it will completely solve the issuer and the actual control under the control of artemisinin-based companies with the competition.
December 31, 2017
Are
As of this announcement, the commitment to strictly fulfill the commitments (1), (2), does not appear contrary to the case of the above commitments.
Commitments associated with refinancing
Solve the related party transactions
Controlling shareholder and actual controller
The controlling shareholder of the Company, of commitments: As the controlling shareholder of Kunming Pharmaceutical, the actual controller, will minimize and regulate related party transactions between its subsidiaries and Kunming Pharmaceutical. For unavoidable or have reasonable grounds related transactions occurred, including but not limited to, commodity trading, providing services to each other, or as a proxy, the company will strictly follow all equivalent, paid the principles of fair trade, fair trade in a market does not require the Kunming Pharmaceutical and its subsidiaries provide superior to any third party or giving third parties the conditions and in accordance with "related trading system" and other normative documents related to the articles of association and the Kunming Pharmaceutical fulfill the legal approval process and enter into related agreements / contract, timely information disclosure norms related transactions, to ensure that no damage to the legitimate interests of related party transactions by Kunming Pharmaceutical and other shareholders, to raise funds to ensure that this issue does not generate new investment projects related party transactions.
No
As of this announcement, the commitment to strictly fulfill this commitment, the commitment does not appear contrary to the above case.
Kunming Pharmaceutical Group Co., Ltd.
Chairman: HE Qin
October 21, 2014
Enter [Reuters shares it] discussion
German Drug Companies Seek Edge by Targeting China
Bayer and Merck Hope Investments, Acquisitions Will Help Them Crack Fast-Growing Market
http://online.wsj.com/articles/german-drug-companies-seek-edge-by-targeting-china-1414512668
This WSJ article is very exciting as is illustrates the potential of Pharmaceuticals in China. Unfortunately, FCPG is not specifically mentioned. However, I did write to the author to see if he came across FCPG in his research.
I'm actually in the Green at .065. My average is now .0549.
What is the growth rate compared to 2010 numbers? And if you carried that growth rate through 2014, what would this year's projections be?
Are you still on this extremely undervalued stock?
The most important and concrete update that has been made about FCPG is in the last two years is in the paragraph. Plus, it is great to see they are hiring and therefore likely expanding.
Nice find Novice! Imagine if FCPG turns out to be the Amazon of prescription drugs for China?
The building does appear to be huge. Just a few cars in the parking lot was my initial concern. Then I noticed there were almost no cars in any of the surrounding parking lots. The picture could have been taken on an off day.
What is everyone estimates of where this stock could go after financials are up to date?
Below are mine.
Beyond our wildest imagination, over $100 : The last two years have seen a growth rate of over 100 percent yearly with little debt:
Outstanding, $40-$100: The last two years have lived up to expectation with 20-30 percent yearly growth. However, the cost of expansion has brought on moderate debt (3 times earnings).
Average, $20-$40: Growth has only been around 10 percent and debt is high because of expansion.
Poor, $10-$20: Growth less than 10 percent and high debt.
Very poor, $1-$10: No growth and high debt.
Oh No, .50-$1: None of the numbers we saw two years ago were close to accurate. FCPG has been bleeding cash. But the financials are up to date and promises will be made for a brighter future.
Even oh no, 10x today's cost.
Around November 19th is my best guess as when we will see financials? What is yours?
Why November 19th? The last financials were released on 11/19/2012. My guess is they are going to want to get everything up to date and sync everything up.
I am probably at the low in at 11,300. Because I added 10,000 of those this week at .045, my effective cost is a little over .06.
Found Financial Statements for Kunming Pharmaceutical Group Co., Ltd.
Is Kunming Pharmaceutical Group part of FCPG. If so, I just found some very positive un-audited current financials. If not, they still show tremendous growth in the pharmaceutical sector.
PDF of Current Financials for Kunming Pharmaceutical Group Co., Ltd.
insert-text-here
Translated Text
Kunming Pharmaceutical Group Co., Ltd.
2014 performance in the first half of the notice should
Board of Directors of the Company and the Directors to ensure that this announcement does not contain any false, misleading statements
Or material omissions, and the truthfulness, accuracy and completeness of individual and joint responsibility.
First, the expected current performance situation
1. Performance notice period: January 1, 2014 to June 30, 2014
2. Performance notice: The net profit growth of 20% -30%
Preliminary estimates by the Company's financial sector, the company expects net profit from January to June 2014 compared with the same period last year increased
Long 20% -30%. Specific data will be disclosed in the company's 2014 semi-annual report.
3. The results are expected after the pre-audit CPA: No
Second, the performance of the previous year
1. Net profit: 116,602,526.41 yuan ($18,656,404)
2. Earnings per share: 0.3711 yuan (.05937)
Third, the main reason for the growth performance
Companies continue to analyze and summarize recent growth performance experience, through the key market planning, key species
Analysis, a subsidiary brand re-planning and carding the first half of 2014 the main products continued to grow, subsidiaries
Division Kunming Pharmaceutical Co., sustained growth performance, Kunming Baker Norton Pharmaceutical Co., Ltd. and Kunming Pharmaceutical Sets
Kim Tae Pharmaceutical Co. group performance resume growth.
The Board of Directors please the majority of investors of investment risks.
Notice is hereby given.
Kunming Pharmaceutical Group Co., Ltd. Board of Directors
July 8, 2014
Announcement of Dividend For Foreign Investors
insert-text-here
Translated Text
Stock Code: 600422 Stock Abbreviation: Kunming Pharmaceutical Bulletin Number: Pro No. 2014-034
Kunming Pharmaceutical Group Co., Ltd.
2013 Annual Dividend Distribution Announcement
The Board of Directors and the Directors to ensure that this announcement does not contain any false,
Misleading statements or material omissions, and the truthfulness, accuracy and completeness
Tam individual and joint responsibility
Important tips:
? pretax 0.35 yuan cash dividend per share.
? outstanding shares of individual shareholders and securities investment fund Zanan 5% withholding tax rate income tax, after-tax per
Share dividend for 0.3325 yuan; Qualified Foreign Institutional Investor (QFII) after-tax dividend of 0.315 per share
Yuan; resident enterprise shareholders (including institutional investors) are not withholding taxes, dividend per share of 0.35
Yuan.
? Record date: June 19, 2014.
? ex (ex) Date: June 20, 2014.
? cash dividend payment date: June 20, 2014.
First, the distribution plan by the shareholders of the General Assembly session times and dates
Company 2013 annual profit distribution plan 2013 annual shareholders' meeting has been held in April 11, 2014
Consideration and adoption. The shareholder resolution was published on April 12, 2014, "Shanghai Securities News", "China
Securities News "," Securities Times "," Securities Daily "and the Shanghai Stock Exchange website
(Http://www.sse.com.cn). The company in May 30, 2014 in the "Shanghai Securities News", "China
Securities News "," Securities Times "," Securities Daily "and the Shanghai Stock Exchange website
(Http://www.sse.com.cn) published "on the deferred payment of 2013 annual cash dividend of suggestive
A 5 percent ownership would be about $150,000, and that is if you did it right now. That is a huge investment on what is still a gamble. Most people on this board probably have between 10,000 and 100,000 shares. A few may have more than 100,000 shares, but I doubt not close to 3 million shares.
I added 10,000 this week because I believe it is a good gamble where the odds are in our favor, but I still understand that it is a gamble.
I am sure there are a number of people who have money on the side waiting for news to break, but are unwilling to put any more in until it does.
I added 10,000 to my position today at .045. I still think it is a gamble, but more like a coin flip. 50/50 if financials ever released. If the are, this $450 investment could be worth over 100 grand shortly there after. That is a huge upside and worth the risk.
I also like CANV, ATW and AFIN. Check them out. All very profitable and undervalued.
Anyone have a clue why is this company is so undervalued?
The Charts (MACD, Stochastics, and 50 Day Moving Average) are pretty flat, but turning in our direction.
I'm a new stock owner. I purchased 175 shares at 2.60 a share today. At this price, I figure there is a heck of a lot more upside than downside.
However, I have no allusions that it will be north of $200 ever again. If they can produce growing profits over the next two quarters then it is reasonable it can be in the $20 - $30 range by next summer.
Anyone know why the stock, and the industry as a whole, dove so fast so quick?
I'm expecting that next weeks quarterly results will be generally positive, but still will fall short of turning a profit because of the 5.5 million one time lawsuit payout. This will send the stock to low 20's, but any significant re-bound is still 3-6 months away when an actual profit is recorded. What are your expectations?
What is everyone expecting out of this quarter? I'm optimistic we could be in the 40's by the start of next week. I got in at $5 range, so an bump is much appreciated.
Enjoying the upward trend, but not sure why. Does anybody have any insight.
Elon tweeted patented news coming at 8:00 am tomorrow (Thursday). Could be a big day for TESLA.
How soon before we can pick up over 100,000 shares for a cool grand and who is going to have guts to do it?
Tornadoes in the Bakken oil field can not be good.
FYI: Fallbrook is a community in San Diego North County. Google Alerts from the Fallbrook Community Planning Group (FCPG). Everytime I get one, I think it's the financials being released.
I expect the numbers to be slightly better than we saw all of last year. But not dramatically better. There will likely be promises that the second half of this year looks very good and some explaining on why additional capitol expenditures are a needed investment for the future.
I really thought there was good chance financials would be reported this week to sink up with so many others. If patience is a virtue, this crowd is approaching Saintly.
What is everyone's thoughts on the financials? I think this stock could make it to $50 by the end of the year. Perhaps sooner if a good chunk of the shorts move on to something else.
I picked of my first 125 shares yesterday as part of my Roth contribution yesterday. In for the long-term and pretty excited about this pick.
And today we got a 10% bump with no news. I guess you have to take the good with the bad. This stock is likely to continue to fluctuate without reason.
However, today's up turn may be a reflection of a positive attitude towards financials being released on Monday.
I am cautiously optimistic that we may get a pleasant surprise, but not overly hopeful because of the poor weather. I just hope we get enough good news in the next 12 months to move the stock north enough to take some profit.
Anyone got a true educated guess on when we will see the numbers?
A friend of mine is the producer of Big Biz Show hosted by Bob “Sully” Sullivan in San Diego. I was in their studio last week and asked the director of all the business they have on the show is their one he would recommend investing in? OOIL was at the top of his list.
I am intrigued by what the company does and looking at their past stock price that is also extremely intriguing. However, I don't know the story.
Why did this stock fall off a cliff? Is there any hope of it truly rebounding? Is this just a penny stock dream that will never go anywhere, or is it worth some cash for a few year investment? Any real insight would be helpful. Thank you!
Thanks for the quick reply. That is about where I thought we were. What are your conservative estimates of where you think this stock really will be at if we get conservative good news? I am thinking of buying just a little bit more.
Looking for an update. Can anyone sum up exactly where we are, and/or a good guess of when numbers will be released. I still remain hopeful this could turn into a profit this year.
Friday could be a big day. On Thursday, (SPWR) announced that the first portion of the 579-megawatt Solar Star development – two projects co-located in Kern and Los Angeles counties in California – was successfully synchronized and is now delivering energy to the California ISO grid.
This is significant because it shows SPWR is on track to complete the project without major delays and this could help land other large projects of similar scope.
I would not be shocked if SPWR doubled in PPS in 2014, which would actually be a major slowing of the PPS growth compared to 2013. I am glad I got in at $5.387. I am just not sure what my target price should be to take some profit. It is in my ROTH, so any profit would need to re-invested elsewhere.